deCODE genetics. About
deCODE: Headquartered in Reykjavik, Iceland,
deCODE is a biopharmaceutical company
applying its discoveries in human genetics
to the development of drugs for common
diseases. deCODE is a global leader in
gene discovery - our population approach
and resources have enabled us to isolate
key genes contributing to major public
health challenges from cardiovascular
disease to cancer, genes that are providing
us with drug targets rooted in the basic
biology of disease. The company currently
has seven lead programs in drug discovery
and development and is broadening its
pipeline through gene and target discovery
work in 50 of the most common diseases.
deCODE is also leveraging its expertise
in human genetics and integrated drug
discovery and development capabilities
to offer innovative products and services
in DNA-based diagnostics, bioinformatics,
genotyping, structural biology, drug discovery
and clinical development. Product
Pipeline Data for deCODE Lead Therapeutic Programs in: Heart
Attck, Atherosclerosis, Asthma, Vascular
Disease, Schizophrenia, Diabetes Type
2 and Obesity More
on deCODE